5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | BUY | BUY | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 4.86▼ | 4.87▼ | 4.89▼ | 4.76▲ | 4.12▲ |
MA10 | 4.87▼ | 4.86▼ | 4.84▲ | 4.53▲ | 4.38▲ |
MA20 | 4.87▼ | 4.80▲ | 4.78▲ | 4.18▲ | 6.03▼ |
MA50 | 4.80▲ | 4.71▲ | 4.59▲ | 4.56▲ | 8.43▼ |
MA100 | 4.76▲ | 4.50▲ | 4.24▲ | 6.10▼ | 13.23▼ |
MA200 | 4.51▲ | 4.15▲ | 4.29▲ | 7.97▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.008▼ | -0.003▼ | -0.006▼ | 0.155▲ | 0.109▲ |
RSI | 49.261▼ | 54.271▲ | 55.843▲ | 58.600▲ | 40.223▼ |
STOCH | 21.779 | 57.702 | 75.895 | 81.021▲ | 17.772▼ |
WILL %R | -76.471▼ | -43.750 | -29.167 | -8.940▲ | -77.020▼ |
CCI | -112.245▼ | 33.086 | 57.252 | 100.877▲ | -37.088 |
Tuesday, May 27, 2025 07:05 AM
AVTX-009 is a humanized monoclonal antibody ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on the transformative ...
|
Monday, May 12, 2025 04:31 AM
AVALO THERAPEUTICS ($AVTX) posted quarterly earnings results on Monday, May 12th. The company reported earnings of -$1.25 per share, beating estimates of -$1.41 by $0 ...
|
Monday, May 12, 2025 04:15 AM
May 12, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/06/25 | 4.68 | 4.95 | 4.68 | 4.84 | 44,230 |
12/06/25 | 4.71 | 4.9499 | 4.62 | 4.88 | 47,041 |
11/06/25 | 4.88 | 4.9783 | 4.59 | 4.71 | 38,386 |
10/06/25 | 4.89 | 4.975 | 4.685 | 4.83 | 128,447 |
09/06/25 | 4.30 | 4.69 | 4.2015 | 4.56 | 197,413 |
06/06/25 | 4.33 | 4.49 | 4.06 | 4.10 | 89,070 |
05/06/25 | 4.31 | 4.50 | 4.15 | 4.33 | 496,002 |
04/06/25 | 4.42 | 4.5466 | 4.125 | 4.35 | 49,690 |
03/06/25 | 4.45 | 4.475 | 4.27 | 4.40 | 69,358 |
02/06/25 | 4.11 | 4.71 | 3.93 | 4.35 | 139,389 |
|
|
||||
|
|
||||
|
|